ZURICH (Reuters) – Roche said on Wednesday its drug Kadcyla, a treatment for an aggressive form of breast cancer, had been approved in Europe following U.S. approval in February.
Kadcyla treats patients with late-stage disease whose cancer cells contain increased amounts of a protein known as HER2.
It works by attaching Herceptin to a drug called DM1, developed by ImmunoGen, which interferes with cancer cell growth. ImmunoGen will receive a $ 5 million milestone payment from Roche following the approval.
(This story corrects to remove reference to Japan approval from the third paragraph)
(Reporting By Katharina Bart; Editing by Andrew Heavens and Louise Heavens)
- Health
- Disease & Medical Conditions
- breast cancer
- ImmunoGen
